Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease

The safety and tolerability of IDE161 is being assessed as part of a phase 1 trial in solid malignancies including breast cancer.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

A health-related quality of life analysis of the phase 3 NATALEE trial supports the risk/benefit profile of adding ribociclib to nonsteroidal aromatase inhibitors in patients with hormone receptor–positive, HER2-negative early breast cancer.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Responses in patients with hormone receptor–positive, HER2-mutated breast cancer who crossed over to receive neratinib plus fulvestrant and trastuzumab support the necessity of neratinib in the triplet regimen.

A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.